LTR Pharma (ASX:LTP) Research & Development: A$4.53 Mil (TTM As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.56
! 1 Warning Sign
View Full Analysis

What is LTR Pharma Research & Development?

LTR Pharma ASX:LTP -4.27% 15 Research & Development is A$4.53 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. LTR Pharma's Research & Development for the six months ended in Dec. 2025 was A$2.57 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$4.53 Mil.

LTR Pharma  (ASX:LTP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

LTR Pharma Research & Development Related Terms

LTR Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Research & Development Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
0.00 0.35 0.82 3.51 2.79

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 1.26 2.24 0.83 1.96 2.57
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$4.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$4.53 Mil mean?
LTR Pharma (ASX:LTP) has a Research & Development of A$4.53 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Research & Development too high?
LTR Pharma's current Research & Development is A$4.53 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Research & Development compare to VRTX and REGN?
LTR Pharma's Research & Development of A$4.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on LTR Pharma and its competitors. LTR Pharma's current Research & Development is A$4.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Research & Development of A$4.53 Mil. The current Research & Development is A$4.53 Mil. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Research & Development is A$4.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price